Quick Takeaways
- This page summarizes Max Rosett's Form 4 filing for Immunome Inc. (IMNM).
- 3 reported transactions and 1 derivative row are listed below.
- Filing timestamp: 20 Sep 2024, 19:26.
Max Rosett - 19 Sep 2024 Form 4 Insider Report for Immunome Inc. (IMNM)
- Signature
- /s/ Sandra Stoneman, Attorney-in-Fact
- Issuer symbol
- IMNM
- Transactions as of
- 19 Sep 2024
- Net transactions value
- -$186,124
- Form type
- 4
- Filing time
- 20 Sep 2024, 19:26:16 UTC
- Previous filing
- 13 Aug 2024
- Next filing
- 31 Jul 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Max Rosett filed Form 4 for Immunome Inc. (IMNM) on 20 Sep 2024."
What Changed
- Previous filing in this sequence was filed on 13 Aug 2024.
- Current net transaction value: -$186,124.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Source Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IMNM | Common Stock | Options Exercise | $44,100 | +42,000 | +212% | $1.05 | 61,856 | 19 Sep 2024 | Direct | |
| transaction | IMNM | Common Stock | Sale | $230,224 | -14,380 | -23% | $16.01 | 47,476 | 19 Sep 2024 | Direct | F1, F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IMNM | Stock option (right to buy) | Options Exercise | $0 | -42,000 | -31% | $0.000000 | 91,848 | 19 Sep 2024 | Common Stock | 42,000 | $1.05 | Direct | F3, F4 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The shares were sold pursuant to sell to cover transactions. |
| F2 | The weighted average sale price for the transaction report was $16.01, and the range of prices were between $15.97 and $16.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. |
| F3 | The Reporting Person's Form 3 filed on October 12, 2023 contains a scrivener's error reflecting an exercise price of $1.06 instead of the correct exercise price of $1.05. |
| F4 | 25% of the shares vested on March 24, 2023, and the remaining shares shall vest in 36 monthly installments thereafter. |